

Highly Specialised Technology Committee Interests Register

Topic: Selpercatinib for advanced thyroid cancer with RET alterations that has not been treated with systemic therapy [ID6132]

Publication Date: 12 February 2025

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Emtiyaz Chowdhury	HST Committee Member	Non-financial Professional Interests	I am employed by Parexel. Parexel is a CRO that offers services to both manufacturers. I am not aware of and have not been involved with any activities related to the technologies under discussion for the meeting on the 12th June.	10/04/2024	It was agreed that Emtiyaz's declaration would not prevent him from participating in discussions on this appraisal.
Jonathan Wadsley	Clinical Expert	Financial interests	<ul style="list-style-type: none"> • My institution has received payments for me to speak at Lilly sponsored educational events and to chair an advisory board. • My institution has also received payments for me to attend advisory boards hosted by Ipsen (regarding comparator cabozantinib). • My institution has also received payments for me to speak at Eisai sponsored educational events and 	10/04/2024	It was agreed that Mr Wadley's declaration would not prevent him from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<p>to attend an advisory board (regarding comparator Lenvatinib)</p> <ul style="list-style-type: none"> • My institution has also received payments for me to speak at Bayer sponsored educational events (regarding comparator Sorafenib) 		
Kee Howe Wong	Clinical Expert	Financial interests	<ul style="list-style-type: none"> • Consultation/advisory role for Lilly – started 25th Nov 2020 and ceased 30th November 2023. 	10/04/2024	It was agreed that Mr Wong's declaration would not prevent him from providing expert advice to the committee.